Shares of Nu Skin Enterprises, Inc. (NYSE:NUS) have received an average rating of “Hold” from the eleven ratings firms that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $62.88.

A number of brokerages have weighed in on NUS. ValuEngine raised shares of Nu Skin Enterprises from a “hold” rating to a “buy” rating in a research note on Friday, June 2nd. Deutsche Bank AG lifted their price target on shares of Nu Skin Enterprises from $63.00 to $66.00 and gave the company a “buy” rating in a research note on Wednesday, June 21st. Pivotal Research reaffirmed a “buy” rating and issued a $80.00 price target (up previously from $65.00) on shares of Nu Skin Enterprises in a research note on Thursday, June 22nd. Zacks Investment Research lowered shares of Nu Skin Enterprises from a “hold” rating to a “sell” rating in a research note on Saturday, June 24th. Finally, Bank of America Corporation lifted their price target on shares of Nu Skin Enterprises from $53.00 to $57.00 and gave the company an “underperform” rating in a research note on Monday, July 10th.

In other news, General Counsel D Matthew Dorny sold 7,500 shares of the business’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $60.88, for a total value of $456,600.00. Following the sale, the general counsel now owns 52,230 shares of the company’s stock, valued at $3,179,762.40. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Daniel W. Campbell sold 4,607 shares of the business’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $62.48, for a total transaction of $287,845.36. Following the completion of the sale, the director now directly owns 63,753 shares in the company, valued at approximately $3,983,287.44. The disclosure for this sale can be found here. In the last three months, insiders sold 28,357 shares of company stock worth $1,783,535. 5.20% of the stock is currently owned by insiders.

Hedge funds have recently made changes to their positions in the company. US Bancorp DE lifted its position in shares of Nu Skin Enterprises by 3.3% in the second quarter. US Bancorp DE now owns 2,032 shares of the company’s stock worth $128,000 after purchasing an additional 65 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Nu Skin Enterprises by 23.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,506 shares of the company’s stock worth $139,000 after purchasing an additional 468 shares in the last quarter. Independent Portfolio Consultants Inc. lifted its position in shares of Nu Skin Enterprises by 14.9% in the second quarter. Independent Portfolio Consultants Inc. now owns 2,730 shares of the company’s stock worth $172,000 after purchasing an additional 355 shares in the last quarter. CENTRAL TRUST Co bought a new stake in shares of Nu Skin Enterprises in the second quarter worth $187,000. Finally, Pillar Pacific Capital Management LLC bought a new stake in shares of Nu Skin Enterprises in the second quarter worth $202,000. 79.25% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Nu Skin Enterprises, Inc. (NUS) Given Consensus Rating of “Hold” by Brokerages” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/18/nu-skin-enterprises-inc-nus-given-consensus-rating-of-hold-by-brokerages.html.

Nu Skin Enterprises (NYSE:NUS) traded down 0.76% on Wednesday, reaching $61.54. 459,178 shares of the company’s stock traded hands. The firm has a market cap of $3.26 billion, a price-to-earnings ratio of 20.58 and a beta of 1.37. Nu Skin Enterprises has a 52-week low of $46.35 and a 52-week high of $66.04. The stock’s 50 day moving average is $60.37 and its 200 day moving average is $57.81.

Nu Skin Enterprises (NYSE:NUS) last released its quarterly earnings data on Wednesday, August 2nd. The company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.08. Nu Skin Enterprises had a net margin of 7.53% and a return on equity of 24.14%. The business had revenue of $550.10 million for the quarter, compared to analyst estimates of $548.09 million. During the same quarter last year, the firm earned $0.79 EPS. Nu Skin Enterprises’s quarterly revenue was down 8.4% compared to the same quarter last year. On average, equities research analysts predict that Nu Skin Enterprises will post $3.23 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 13th. Shareholders of record on Friday, August 25th were paid a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a yield of 2.34%. The ex-dividend date of this dividend was Wednesday, August 23rd. Nu Skin Enterprises’s payout ratio is currently 48.81%.

Nu Skin Enterprises Company Profile

Nu Skin Enterprises, Inc is a direct selling company that develops and distributes personal care products and nutritional supplements, and a range of other products and services. The Company offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Nu Skin brand offers a range of products, including ageLOC Me customized skin care system, ageLOC Spa systems and ageLOC Transformation anti-aging skin care system.

Analyst Recommendations for Nu Skin Enterprises (NYSE:NUS)

Receive News & Stock Ratings for Nu Skin Enterprises Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises Inc. and related stocks with our FREE daily email newsletter.